Farhad Dastmalchi has developed a novel vaccines that have resulted in improved survival through his research in developing immunotherapy vaccines. He is an assistant scientist with the Preston A. Wells Jr. Center for Brain Tumor Therapy in order to focus on developing novel approaches to target and treat brain tumors.
Areas of Expertise (5)
Cancer Vaccine Development
Glioma Immunotherapy: Advances and Challenges for Spinal Cord GliomasSpine and Spinal Cord Tumors
Clare Grady, et al.
Spinal cord gliomas are rare entities that often have limited surgical options. Immunotherapy has shown promise in intracranial gliomas with some research suggesting benefit for spinal cord gliomas. A focused review of immunotherapies that have been investigated in spinal cord gliomas was performed. The primary methods of immunotherapy investigated in spinal cord gliomas include immune checkpoint inhibitors, adoptive T-cell therapies, and vaccine strategies.
Contemporary RNA Therapeutics for GlioblastomaNeuroMolecular Medicine
Kaitlyn Melnick, et al.
Glioblastoma (GBM) is the most common primary brain tumor in adults and is universally lethal with a median survival of less than two years with standard therapy. RNA-based immunotherapies have significant potential to establish a durable treatment response for malignant brain tumors including GBM. RNA offers clear advantages over antigen-focused approaches but cannot often be directly administered due to biological instability.
Metabolomics Monitoring of Treatment Response to Brain Tumor ImmunotherapyCancer Metabolism
Farhad Dastmalchi, et al.
Immunotherapy has revolutionized care for many solid tissue malignancies, and is being investigated for efficacy in the treatment of malignant brain tumors. Identifying a non-invasive monitoring technique such as metabolomics monitoring to predict patient response to immunotherapy has the potential to simplify treatment decision-making and to ensure therapy is tailored based on early patient response.